Erasmus Partnership Part of Ingenuity's 'Significant Investment' in NGS Data Analysis | GenomeWeb

By Uduak Grace Thomas

Ingenuity Systems said this week that Erasmus Medical Center will use its pathway informatics tools to analyze next-generation sequence data for cancer research studies.

The partnership will serve as a "validation of IPA's role in NGS research and its ability to provide meaningful insights for researchers leveraging NGS data," Doug Basset, chief scientific officer and chief technology officer for Ingenuity, said in a statement.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.